Germline PALB2 pathogenic variants were associated with an increased risk for female breast cancer, male breast cancer, ovarian cancer, and pancreatic cancer, and these risks varied by age, according to data from an international study recently that was published in the Journal of Clinical Oncology.
The study included 524 families made up of 17,906 individuals from 21 countries. Eligible families had at least 1 family member with a PALB2 pathogenic variant. Families with a known BRCA1/BRCA2 pathogenic variant were excluded. Read more . . .